Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NIASPAN vs FENOGLIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Niacin (nicotinic acid) reduces hepatic production of VLDL and LDL, and increases HDL by inhibiting diacylglycerol acyltransferase-2 (DGAT2) and reducing hepatic triglyceride synthesis. It also decreases the catabolism of HDL apolipoproteins A-I and A-II.
Fenofibrate is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It increases lipolysis and elimination of triglyceride-rich particles from plasma, reduces hepatic production of VLDL, and increases HDL cholesterol.
Primary dyslipidemia and mixed dyslipidemia as an adjunct to diet,Hypertriglyceridemia in patients at risk of pancreatitis,Reduction of risk of myocardial infarction in patients with hyperlipidemia and history of MI,Secondary prevention of cardiovascular events in combination with statin,Off-label: Prevention of pellagra (niacin deficiency)
Primary hypercholesterolemia,Mixed dyslipidemia,Severe hypertriglyceridemia
Starting dose: 500 mg orally once daily at bedtime; after 4 weeks, increase to 1000 mg once daily; then titrate to maintenance dose of 1500-2000 mg once daily; maximum dose: 2000 mg/day.
160 mg orally once daily, taken with or without food.
Terminal half-life is 20-45 minutes (immediate-release) but due to prolonged release formulation of Niaspan, the half-life is extended to 2-4 hours for total nicotinic acid and 12 hours for nicotinuric acid, allowing once-daily dosing.
The terminal elimination half-life of fenofibric acid is approximately 20 hours (range 15-25 hours). This long half-life allows once-daily dosing. Steady-state is reached within approximately 5 days.
Primarily hepatic metabolism via two pathways: conjugation with glycine to form nicotinuric acid (major pathway, saturable) and conversion to nicotinamide adenine dinucleotide (NAD). Minor metabolism via oxidation to N-methylnicotinamide and other metabolites.
Hepatic metabolism via glucuronidation; minor CYP450 involvement (CYP3A4).
Primarily renal (60-76% as unchanged drug and metabolites). Hepatic metabolism is extensive; less than 2% excreted in feces.
Fenoglide (fenofibrate) is primarily excreted in urine as fenofibric acid and its glucuronide conjugate, accounting for approximately 60-70% of the dose. About 20-25% is eliminated in feces via biliary excretion. Renal excretion is the major route.
<20% bound to plasma proteins (mainly albumin). Binding is negligible at therapeutic concentrations.
Fenofibric acid is extensively bound to plasma proteins, primarily albumin, with a binding rate greater than 99%.
Approximately 0.5 L/kg (around 35 L in a 70 kg adult), indicating distribution into total body water.
The apparent volume of distribution (Vd) of fenofibric acid is approximately 0.9 L/kg. This suggests distribution into total body water, with some tissue binding.
Oral (extended-release): ~60-76% due to extensive first-pass metabolism. Bioavailability is dose-dependent and saturable at higher doses.
The absolute oral bioavailability of fenofibric acid from fenofibrate tablets is approximately 90% under fed conditions. Administration with food increases absorption by up to 35% compared to fasting.
No specific dose adjustment provided by manufacturer; use with caution in patients with renal impairment; avoid in patients with severe renal impairment or nephrotic syndrome.
No dose adjustment required for mild to moderate renal impairment (e GFR >30 m L/min/1.73 m2). Not recommended in severe renal impairment (e GFR <30 m L/min/1.73 m2) or dialysis.
Contraindicated in patients with significant or unexplained hepatic dysfunction; use with caution in patients with Child-Pugh class A, avoid in Child-Pugh class B or C.
Contraindicated in severe hepatic impairment (Child-Pugh class C). Use caution in moderate impairment (Child-Pugh class B); consider dose reduction.
Safety and efficacy not established in pediatric patients; not recommended for use.
Not approved for use in pediatric patients under 18 years of age.
No specific dose adjustment recommended; monitor for adverse effects such as myopathy and hepatotoxicity; initiate at low end of dosing range.
No specific dose adjustment; monitor renal function due to age-related decline.
No FDA black box warning.
No FDA black box warning.
Hepatotoxicity: elevated liver enzymes, rare severe hepatotoxicity; avoid in patients with active liver disease,Flushing: prostaglandin-mediated, can be reduced by taking aspirin or starting with low doses,Hyperglycemia: may increase blood glucose, use with caution in diabetic patients,Hyperuricemia: may precipitate gout, monitor uric acid,Gastrointestinal effects: can cause peptic ulcer, use caution with history of GI bleeding,Cardiovascular: may cause hypotension, especially with concurrent use of antihypertensives
Hepatotoxicity: rare but severe; monitor liver enzymes.,Rhabdomyolysis: risk increased with renal impairment, hypothyroidism, statins.,Renal function: dose adjustment needed in mild-moderate impairment; contraindicated in severe renal disease.,Cholelithiasis: fenofibrate increases cholesterol excretion into bile.,Pancreatitis: associated with severe hypertriglyceridemia; monitor triglycerides.,Venous thromboembolism: increased risk with fenofibrate.
Active liver disease or unexplained transaminase elevations,Active peptic ulcer disease,Arterial bleeding,Hypersensitivity to niacin or any component of the formulation
Severe renal impairment (e GFR <30 m L/min/1.73m²),Active liver disease including primary biliary cirrhosis,Known hypersensitivity to fenofibrate or excipients,Gallbladder disease,Nursing mothers
Avoid alcohol, hot beverages, and spicy foods near dose time as they can worsen flushing. Take with a low-fat snack (e.g., apple, rice cakes) to reduce gastrointestinal upset and flushing. Avoid high-fat meals which may increase risk of flushing. Grapefruit juice has no significant interaction but other fruit juices have not been studied; advise moderate intake.
Take with food to enhance absorption. Avoid high-fat meals immediately before or after dose. Grapefruit juice may increase fenofibrate exposure (moderate interaction, monitor). Statin co-administration: avoid large amounts of grapefruit juice.
Niacin (NIASPAN) is classified as FDA Pregnancy Category C. Animal studies have shown adverse effects at high doses, but there are no adequate and well-controlled studies in pregnant women. Niacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. There is no evidence of teratogenicity in humans at recommended doses, but high doses may cause fetal harm.
First trimester: No adequate studies; animal data show no major malformations at clinically relevant doses. Second and third trimesters: Associated with adverse maternal and fetal outcomes (e.g., preterm birth, low birth weight) due to β-receptor agonist effects. Avoid use during pregnancy.
Niacin is excreted in human breast milk in amounts that are likely comparable to maternal plasma levels. The milk-to-plasma (M/P) ratio for niacin is approximately 1.0. The American Academy of Pediatrics considers niacin compatible with breastfeeding at usual dietary intakes, but high pharmacological doses should be avoided due to potential adverse effects in the infant, such as flushing and gastrointestinal disturbances.
Excreted in breast milk; M/P ratio unknown. Potential for neonatal β-receptor stimulation. Caution advised; manufacturer recommends discontinuing breastfeeding or drug.
No specific dose adjustments are recommended for niacin during pregnancy due to lack of data on pharmacokinetic changes. However, doses should be kept at the lowest effective level and used only when clearly needed. There is no evidence that pregnancy alters niacin clearance or requires dose modification.
No established dose adjustments for pregnancy; use only if potential benefit outweighs risk. Consideration of lower doses due to altered pharmacokinetics (increased clearance, decreased plasma concentration).
Niacin extended-release (NIASPAN) causes flushing, which can be mitigated by taking aspirin 30 minutes before dosing, avoiding alcohol and hot beverages at time of dosing, and initiating at low dose with gradual titration. Liver function tests must be monitored; elevation >3x ULN requires discontinuation. NIASPAN can exacerbate gout by increasing uric acid levels; check uric acid at baseline and periodically. Use with caution in diabetes as it may increase glucose levels. Avoid in patients with active liver disease, unexplained transaminase elevations, or peptic ulcer disease.
Fenofibrate is a fibric acid derivative used primarily for hypertriglyceridemia and mixed dyslipidemia. It activates PPAR-alpha, increasing lipoprotein lipase and reducing apolipoprotein C-III. Monitor renal function; dose adjustment required for Cr Cl 30-60 m L/min. Contraindicated in severe renal impairment (Cr Cl <30) and active liver disease. Can increase serum creatinine, but this is often reversible. Co-administration with statins increases risk of myopathy, especially in elderly or renal impairment. May increase homocysteine levels; monitor if at risk for thrombosis.
Take NIASPAN at bedtime with a low-fat snack to reduce flushing.,Do not take on an empty stomach; avoid alcohol and hot drinks near dose time.,Flushing may occur but usually decreases over weeks; can take aspirin 30 minutes prior to dose.,Do not miss doses; if a dose is missed, do not double up the next day.,Common side effects include flushing, itching, and tingling; report severe or persistent effects.,Your doctor will monitor blood glucose, uric acid, and liver function regularly.,Do not substitute with other niacin preparations without doctor approval.
Take with food to improve absorption.,Avoid alcohol as it may worsen triglyceride levels.,Report unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever or malaise.,Do not stop medication without consulting your doctor, even if you feel well.,Keep all appointments for blood tests to monitor liver function and lipid levels.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NIASPAN vs FENOGLIDE, answered by our medical review team.
NIASPAN is a Antilipemic agent that works by Niacin (nicotinic acid) reduces hepatic production of VLDL and LDL, and increases HDL by inhibiting diacylglycerol acyltransferase-2 (DGAT2) and reducing hepatic triglyceride synthesis. It also decreases the catabolism of HDL apolipoproteins A-I and A-II.. FENOGLIDE is a Antilipemic that works by Fenofibrate is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It increases lipolysis and elimination of triglyceride-rich particles from plasma, reduces hepatic production of VLDL, and increases HDL cholesterol.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NIASPAN and FENOGLIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NIASPAN is: Starting dose: 500 mg orally once daily at bedtime; after 4 weeks, increase to 1000 mg once daily; then titrate to maintenance dose of 1500-2000 mg once daily; maximum dose: 2000 mg/day.. The standard adult dose of FENOGLIDE is: 160 mg orally once daily, taken with or without food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NIASPAN and FENOGLIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NIASPAN is classified as Category C. Niacin (NIASPAN) is classified as FDA Pregnancy Category C. Animal studies have shown adverse effects at high doses, but there are no adequate and well-controlled studies in pregna. FENOGLIDE is classified as Category C. First trimester: No adequate studies; animal data show no major malformations at clinically relevant doses. Second and third trimesters: Associated with adverse maternal and fetal . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.